<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nid-980</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита</article-title><trans-title-group xml:lang="en"><trans-title>Influence of hereditary thrombophilia (HT) on clinical features and pathology finding in chronic glomerulonephritis (CGN) patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боброва</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bobrova</surname><given-names>L. A.</given-names></name></name-alternatives><email xlink:type="simple">MrLee2005@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козловская</surname><given-names>Н. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlovskaya</surname><given-names>N. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шкарупо</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shkarupo</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Варшавский</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Varshavsky</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Столяревич</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Stoliarevich</surname><given-names>E. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра нефрологии и гемодиализа ФППОВ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of nephrology and hemodialysis, Faculty of post-graduate education, Research Institute of molecular medicine, laboratory of human molecular genetics, Department of pathology, Moscow Medical Academy; Department of nephrology Moscow City Medical Dental University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>НИИ молекулярной медицины, лаборатория молекулярной генетики человека</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of nephrology and hemodialysis, Faculty of post-graduate education, Research Institute of molecular medicine, laboratory of human molecular genetics, Department of pathology, Moscow Medical Academy; Department of nephrology Moscow City Medical Dental University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>кафедра патологической анатомии ММА им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of nephrology and hemodialysis, Faculty of post-graduate education, Research Institute of molecular medicine, laboratory of human molecular genetics, Department of pathology, Moscow Medical Academy; Department of nephrology Moscow City Medical Dental University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>кафедра нефрологии ФПДО МГСМУ г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of nephrology and hemodialysis, Faculty of post-graduate education, Research Institute of molecular medicine, laboratory of human molecular genetics, Department of pathology, Moscow Medical Academy; Department of nephrology Moscow City Medical Dental University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>17</day><month>06</month><year>2025</year></pub-date><volume>12</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Боброва Л.А., Козловская Н.Л., Шкарупо В.В., Варшавский В.А., Столяревич Е.С., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Боброва Л.А., Козловская Н.Л., Шкарупо В.В., Варшавский В.А., Столяревич Е.С.</copyright-holder><copyright-holder xml:lang="en">Bobrova L.A., Kozlovskaya N.L., Shkarupo V.V., Varshavsky V.A., Stoliarevich E.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/980">https://journal.nephro.ru/jour/article/view/980</self-uri><abstract><p>Цель работы: оценить влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения ХГН. Материалы и методы: были проанализированы клиническая картина и данные биопсии почки 25 больных (12 женщин, ср. возраст 32 ± 12 лет и 13 мужчин, ср. возраст 36 ± 8,8 лет), госпитализированных в клинику с диагнозом «хронический гломерулонефрит». Средняя длительность почечного анамнеза к моменту проведения биопсии составила 42,1 мес. Критериями отбора пациентов для выполнения генетического исследования были: тромбозы различной локализации, у женщин – синдром потери плода или ранней преэклампсии (до 34 недели беременности), с сохраняющимися более 6 месяцев после родов изменениями в анализах мочи и/или артериальной гипертензией; АГ, не соответствующая активности почечного процесса; изолированное или несопоставимое со степенью повышения уровня сывороточного креатинина (sCr) снижение скорости клубочковой фильтрации (СКФ); отрицательные серологические маркеры АФС. Оценивали основные клинико-лабораторные параметры на момент выполнения биопсии почки. Почечным исходом считали стабильное повышение уровня Scr &gt; 1,4 мг/дл в течение 6 мес. Методом ПЦР определяли полиморфизмы генов MTHFR С677Т; PTG G20210A; FV Leiden G1691A; FGB G455A; ITGB3 T176C L33P; PAI-1 4G/5G 675. Результаты: мутация в одном гене была выявлена у 24% больных, мультигенная форма тромбофилии – у 76% больных. У всех больных при морфологическом исследовании ткани почки были обнаружены признаки ТМА, у 8 из них – сочетание острой и хронической ТМА. У 3 (13%) пациентов ТМА была единственным гистологическим признаком нефропатии, у остальных сочеталась с различными морфологическими вариантами ХГН. Наибольшая выраженность склеротических изменений отмечалась при одновременном носительстве аллелей 4G PAI-1 и Т MTHFR. «Почечный исход» коррелировал с количеством мутантных аллелей (r = 0,6; p &gt; 0,05), наличием аллеля 4G (r = 0,46; p = 0,05), и склероза интерстиция (r = 0,5; p = 0,05). Заключение: наследственная тромбофилия способствует индукции нефросклероза, по-видимому, приводя к активации внутриклубочкового свертывания крови, что может вносить вклад в прогрессирование ХГН. У больных с генетической формой тромбофилии возможно развитие острой ТМА как единственного варианта поражения почек.</p></abstract><trans-abstract xml:lang="en"><p>Aim: to characterize clinical features and pathology of chronic glomerulonephritis (CGN) in patients with genetic thrombophilia. Material and methods. Morphological data of 25 pts (12 F, 13 M, 34,0 ± 10,6 years) with HT diagnosed with CGN were analyzed. Average duration of nephropathy at biopsy time was 41,2 months. Criteria of patients’ selection for genetic analysis were: clinical manifestation of thromboses of various localization; syndrome of fetus loss, especially with early preeclampsia (earlier than 34 weeks of pregnancy), arterial hypertension which is inappropriate to the activity of renal disease; negative serological markers of APS. Polymorphisms of genes MTHFR С677Т; PTG G20210A; FV Leiden G1691A; FGB G455A; ITGB3 T176C L33P; PAI-1 4G/5G 675 were determined with PCR. For each biopsy glomerulosclerosis, arterio/arteriolosclerosis and the degree of interstitial fibrosis were analyzed semiquantitatively. Results. Mutation in one of the genes was detected in 24% patients, a multigenic form of thrombophilia – in 76% patients. All 25 patients had biopsy proven TMA, 3 of them had a combination of acute and chronic TMA features. ТМА was the only morphological sign of nephropathy in 3 (13%) pts. TMA was combined with various morphological variants of CGN in all other pts: mesangioproliferative CGN – in 39% pts including 2 with IgA – nephropathy, membranous CGN – in 8% and membranoproliferative CGN I type in 4%, 16% pts had FSGS, 5 (20%) – nephrosclerosis. Sclerotic alterations were more severe in combined carriage of the alleles 4G PAI-1 and T MTHFR. A correlation was found between the renal end point and number of mutant alleles (r = 0,6; p &lt; 0,05), the presence of allele 4G (r = 0,46; p = 0,05) and interstitial sclerosis (r = 0,5; p = 0,05). Conclusion. Hereditary thrombophilia promotes induction of nephrosclerosis, leads to activation of intraglomerular blood clotting which contributes to the CGN progression. Patients with genetic thrombophilia may develop acute TMA without any other kinds of renal damage.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический гломерулонефрит</kwd><kwd>тромботическая микроангиопатия</kwd><kwd>тромбофилия</kwd><kwd>нефроангиосклероз</kwd><kwd>chronic glomerulonephritis</kwd><kwd>thrombotic microangiopathy</kwd><kwd>thrombophilia</kwd><kwd>nephroangiosclerosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Авдонин П.В., Кириенко А.И., Кожевникова Л.М., Шостак Н.А. и др. Корреляция наличия мутации С677Т в гене метилентетрагидрофолатредуктазы и повышенный риск тромбоэмболии легочных артерий у больных из центрального региона России с венозными тромбозами // Тер. Архив. 2006. №6. С. 70–71.</mixed-citation><mixed-citation xml:lang="en">Авдонин П.В., Кириенко А.И., Кожевникова Л.М., Шостак Н.А. и др. Корреляция наличия мутации С677Т в гене метилентетрагидрофолатредуктазы и повышенный риск тромбоэмболии легочных артерий у больных из центрального региона России с венозными тромбозами // Тер. Архив. 2006. №6. С. 70–71.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Андреенко Г.В., Полянцева Л.Р., Подорольская Л.В. Фибринолитические свойства плазмы крови, мочи и отечных жидкостей у больных с нефротическим синдромом // Тер Архив. 1982. №7. С. 53–57.</mixed-citation><mixed-citation xml:lang="en">Андреенко Г.В., Полянцева Л.Р., Подорольская Л.В. Фибринолитические свойства плазмы крови, мочи и отечных жидкостей у больных с нефротическим синдромом // Тер Архив. 1982. №7. С. 53–57.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Балуда В.П., Балуда М.В., Деянов И.И., Тлепшуков И.К. Физиология системы гемостаза. М., 1995.</mixed-citation><mixed-citation xml:lang="en">Балуда В.П., Балуда М.В., Деянов И.И., Тлепшуков И.К. Физиология системы гемостаза. М., 1995.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Калашникова Е.А., Кокаровцева С.Н., Коваленко Т.Ф. и др. Частоты мутаций в генах фактора V (FV Leiden), протромбина (G20210A) и 5,10-метилентетрагидрофолатредуктазы (C677T) у русских // Мед. генетика. 2006. №7. С. 27–29.</mixed-citation><mixed-citation xml:lang="en">Калашникова Е.А., Кокаровцева С.Н., Коваленко Т.Ф. и др. Частоты мутаций в генах фактора V (FV Leiden), протромбина (G20210A) и 5,10-метилентетрагидрофолатредуктазы (C677T) у русских // Мед. генетика. 2006. №7. С. 27–29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Козловская Л.В., Бобкова И.Н., Плиева О.К. и др. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите // Тер Архив. 2004. №9. С. 84–87.</mixed-citation><mixed-citation xml:lang="en">Козловская Л.В., Бобкова И.Н., Плиева О.К. и др. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите // Тер Архив. 2004. №9. С. 84–87.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Козловская Н.Л., Шилов Е.М., Метелева Н.А. Клинико-морфологические особенности нефропатии при первичном и вторичном АФС // Тер Архив. 2007. №6. С. 16–25.</mixed-citation><mixed-citation xml:lang="en">Козловская Н.Л., Шилов Е.М., Метелева Н.А. Клинико-морфологические особенности нефропатии при первичном и вторичном АФС // Тер Архив. 2007. №6. С. 16–25.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Козловская Н.Л., Швецов М.Ю., Козловская Л.В. Поражение почек у больных системной красной волчанкой с антифосфолипидным синдромом и первичным антифосфолипидным синдромом. Успехи нефрологии. М.: ММА им. И.М. Сеченова, 2001. С. 227–236.</mixed-citation><mixed-citation xml:lang="en">Козловская Н.Л., Швецов М.Ю., Козловская Л.В. Поражение почек у больных системной красной волчанкой с антифосфолипидным синдромом и первичным антифосфолипидным синдромом. Успехи нефрологии. М.: ММА им. И.М. Сеченова, 2001. С. 227–236.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Никитина Л.А., Демидова Е.М., Садекова О.Н. и др. Роль некоторых генетических полиморфизмов в невынашивании беременности // Проблемы репродукции. 2007. №6. С. 83–89.</mixed-citation><mixed-citation xml:lang="en">Никитина Л.А., Демидова Е.М., Садекова О.Н. и др. Роль некоторых генетических полиморфизмов в невынашивании беременности // Проблемы репродукции. 2007. №6. С. 83–89.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs // Am J Hematol. 2002. Vol. 71 (2). P. 89–93.</mixed-citation><mixed-citation xml:lang="en">Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs // Am J Hematol. 2002. Vol. 71 (2). P. 89–93.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Behague I., Poirier O., Nicaud V. et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study // Circulation. 1996. Vol. 93. P. 440–449.</mixed-citation><mixed-citation xml:lang="en">Behague I., Poirier O., Nicaud V. et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study // Circulation. 1996. Vol. 93. P. 440–449.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders // Kidney Int. 2006. Vol. 70. P. 423–431.</mixed-citation><mixed-citation xml:lang="en">Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders // Kidney Int. 2006. Vol. 70. P. 423–431.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Canavy I., Henry M., Morange P.E. et al. Genetic polymorphisms and coronary artery disease in the south of France // Thromb Haemost. 2000. Vol. 83. P. 212–216.</mixed-citation><mixed-citation xml:lang="en">Canavy I., Henry M., Morange P.E. et al. Genetic polymorphisms and coronary artery disease in the south of France // Thromb Haemost. 2000. Vol. 83. P. 212–216.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Caletti M.G. et al. Development of focal segmental sclerosis and hyalinosis in haemolytic uremic syndrome // Pediatr Nephrol. 1996. Vol. 10. P. 687–692.</mixed-citation><mixed-citation xml:lang="en">Caletti M.G. et al. Development of focal segmental sclerosis and hyalinosis in haemolytic uremic syndrome // Pediatr Nephrol. 1996. Vol. 10. P. 687–692.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Сhoi B.O., Kim N.K., Kim S.H. et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small artery occlusions // Thromb Res. 2003. Vol. 111 (1–2). P. 39–44.</mixed-citation><mixed-citation xml:lang="en">Сhoi B.O., Kim N.K., Kim S.H. et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small artery occlusions // Thromb Res. 2003. Vol. 111 (1–2). P. 39–44.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng-Hsu Chen, Kuo-Hsiung Shul, Mei-Chin Wen et al. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy // Nephrol Dial Transplant. 2008. Vol. 23. P. 3166–3173.</mixed-citation><mixed-citation xml:lang="en">Cheng-Hsu Chen, Kuo-Hsiung Shul, Mei-Chin Wen et al. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy // Nephrol Dial Transplant. 2008. Vol. 23. P. 3166–3173.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Daugas E, Nochy D, Thi Huong D L et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus // J Am Soc Nephrol. 2002. Vol. 13. P. 42–52.</mixed-citation><mixed-citation xml:lang="en">Daugas E, Nochy D, Thi Huong D L et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus // J Am Soc Nephrol. 2002. Vol. 13. P. 42–52.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dawson S.J., Wiman B., Hamsten A. et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells // J Biol Chem. 1993. Vol. 268. P. 10739–10745.</mixed-citation><mixed-citation xml:lang="en">Dawson S.J., Wiman B., Hamsten A. et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells // J Biol Chem. 1993. Vol. 268. P. 10739–10745.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Doggen C.J., Cats V.M., Bertina R.M., Rosendaal F.R. Interaction of coagulation defects and cardiovascular risk factor: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A // Circulation. 1998. Vol. 97. P. 1037–1041.</mixed-citation><mixed-citation xml:lang="en">Doggen C.J., Cats V.M., Bertina R.M., Rosendaal F.R. Interaction of coagulation defects and cardiovascular risk factor: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A // Circulation. 1998. Vol. 97. P. 1037–1041.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fowkes F.G.R., Connar J.M., Smith F.B. et al. Fibrinogen genotype and risk of peripheral atherosclerosis // Lancet. 1992. Vol. 339. P. 639–646.</mixed-citation><mixed-citation xml:lang="en">Fowkes F.G.R., Connar J.M., Smith F.B. et al. Fibrinogen genotype and risk of peripheral atherosclerosis // Lancet. 1992. Vol. 339. P. 639–646.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Goforth RL, Rennke H, Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias // Kidney Int. 2006. Vol. 70. P. 743–750.</mixed-citation><mixed-citation xml:lang="en">Goforth RL, Rennke H, Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias // Kidney Int. 2006. Vol. 70. P. 743–750.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gong R., Liu Z., Li L. Epistatic effect of plasminogen activator inhibitor I and b-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis // Arthritis Rheum. 2007. Vol. 56. P. 1608–1617.</mixed-citation><mixed-citation xml:lang="en">Gong R., Liu Z., Li L. Epistatic effect of plasminogen activator inhibitor I and b-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis // Arthritis Rheum. 2007. Vol. 56. P. 1608–1617.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hamano K., Iwano M., Akai Y. et al. Exspression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis // Am J Kidney Dis. 2002. Vol. 39. P. 695–705.</mixed-citation><mixed-citation xml:lang="en">Hamano K., Iwano M., Akai Y. et al. Exspression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis // Am J Kidney Dis. 2002. Vol. 39. P. 695–705.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hoekstra T., Geleijnse J.M., Schouten E.G., Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk // Thromb Haemost. 2004. Vol. 91. P. 861–862.</mixed-citation><mixed-citation xml:lang="en">Hoekstra T., Geleijnse J.M., Schouten E.G., Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk // Thromb Haemost. 2004. Vol. 91. P. 861–862.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kant K.S, Pollak V.E, Weiss M.A. et al. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance // Medicine. 1981. Vol. 60 (7). P. 71–85.</mixed-citation><mixed-citation xml:lang="en">Kant K.S, Pollak V.E, Weiss M.A. et al. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance // Medicine. 1981. Vol. 60 (7). P. 71–85.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Koupepidou P., Deltas C., Christofides T.C. et al. The MHTFR 677TT and 677CT/128AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure // Int Angiol. 2005. Vol. 24. P. 287–294.</mixed-citation><mixed-citation xml:lang="en">Koupepidou P., Deltas C., Christofides T.C. et al. The MHTFR 677TT and 677CT/128AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure // Int Angiol. 2005. Vol. 24. P. 287–294.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lane D.A., Mannucci P.M., Bauer K.A. et al. Inherited thrombophilia. Part I [Review] // Thromb Haemost. 1996. Vol. 76. P. 651–662.</mixed-citation><mixed-citation xml:lang="en">Lane D.A., Mannucci P.M., Bauer K.A. et al. Inherited thrombophilia. Part I [Review] // Thromb Haemost. 1996. Vol. 76. P. 651–662.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lee D.H., Henderson P.A., Blajchman M.A. Prevalence of Factor V Leiden in a Canadian blood donor population // Canadian Medical Association Journal. 1996. Vol. 155 (3). P. 285–289.</mixed-citation><mixed-citation xml:lang="en">Lee D.H., Henderson P.A., Blajchman M.A. Prevalence of Factor V Leiden in a Canadian blood donor population // Canadian Medical Association Journal. 1996. Vol. 155 (3). P. 285–289.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Marcantoni C., Fogo A.B. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis // Journ Nephrol. 2007. Vol. 20. P. 518–524.</mixed-citation><mixed-citation xml:lang="en">Marcantoni C., Fogo A.B. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis // Journ Nephrol. 2007. Vol. 20. P. 518–524.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Martiskainen M., Pohjasvaara T., Mikkelsson J. et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke // Stroke. 2003. Vol. 34. P. 886–891.</mixed-citation><mixed-citation xml:lang="en">Martiskainen M., Pohjasvaara T., Mikkelsson J. et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke // Stroke. 2003. Vol. 34. P. 886–891.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mello G., Parretti E., Marozio L. et al. Thrombophilia is significantly associated with severe preeclampsia // Hypertension. 2005. Vol. 46. P. 1270.</mixed-citation><mixed-citation xml:lang="en">Mello G., Parretti E., Marozio L. et al. Thrombophilia is significantly associated with severe preeclampsia // Hypertension. 2005. Vol. 46. P. 1270.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nochy D., Daugas E., Droz D. et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome // J Am Soc Nephrol. 1999. Vol. 10. P. 507–518.</mixed-citation><mixed-citation xml:lang="en">Nochy D., Daugas E., Droz D. et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome // J Am Soc Nephrol. 1999. Vol. 10. P. 507–518.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Paueksakon P, Revelo M.P, Ma L.J, et al. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy // Kidney Intern. 2002. Vol. 61. P. 2142–2148.</mixed-citation><mixed-citation xml:lang="en">Paueksakon P, Revelo M.P, Ma L.J, et al. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy // Kidney Intern. 2002. Vol. 61. P. 2142–2148.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggenenti P., Remuzzi G. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy // Am J Kidney Dis. 1996. Vol. 27. P. 459–475.</mixed-citation><mixed-citation xml:lang="en">Ruggenenti P., Remuzzi G. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy // Am J Kidney Dis. 1996. Vol. 27. P. 459–475.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sirotkina O., Merkulova A., Chukhlovina M., Elchaninov P. The 4g/5g Polymorphism of the PAI-1 Gene is Associated with Cerebrovascular Disease Development in Childhood and Juvenile Period // Journal of Thrombosis and Haemostasis. 2005. Vol. 3 (Suppl. 1). P. 1606 (Abstract).</mixed-citation><mixed-citation xml:lang="en">Sirotkina O., Merkulova A., Chukhlovina M., Elchaninov P. The 4g/5g Polymorphism of the PAI-1 Gene is Associated with Cerebrovascular Disease Development in Childhood and Juvenile Period // Journal of Thrombosis and Haemostasis. 2005. Vol. 3 (Suppl. 1). P. 1606 (Abstract).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Sucker C., Kurschat C., Farokhzad F. et al. The TT Genotype of the C677T Polymorphism in the Methylentetrahydrofolate Reductase as a Risk Factor in Thrombotic Microangiopathies: Results From a Pilot Study // Clin Appl Thromb Hemost. 2009. Vol. 15. P. 283–289.</mixed-citation><mixed-citation xml:lang="en">Sucker C., Kurschat C., Farokhzad F. et al. The TT Genotype of the C677T Polymorphism in the Methylentetrahydrofolate Reductase as a Risk Factor in Thrombotic Microangiopathies: Results From a Pilot Study // Clin Appl Thromb Hemost. 2009. Vol. 15. P. 283–289.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki H.; Sakuma Y.; Kanesaki Y. et al. Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy // Clinical nephrology. 2004. Vol. 62. P. 173–179.</mixed-citation><mixed-citation xml:lang="en">Suzuki H.; Sakuma Y.; Kanesaki Y. et al. Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy // Clinical nephrology. 2004. Vol. 62. P. 173–179.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tectonidou M.G., Sotsiou F., Nakopoulou L. et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations and long-term outcome // Arthritis Rheum. 2004. Vol. 50 (8). P. 2569–2579.</mixed-citation><mixed-citation xml:lang="en">Tectonidou M.G., Sotsiou F., Nakopoulou L. et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations and long-term outcome // Arthritis Rheum. 2004. Vol. 50 (8). P. 2569–2579.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Wiklund P.-G., Nilsson L., Nilsson Ardnor S. et al. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke // Stroke. 2005. Vol. 36. P. 1661.</mixed-citation><mixed-citation xml:lang="en">Wiklund P.-G., Nilsson L., Nilsson Ardnor S. et al. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke // Stroke. 2005. Vol. 36. P. 1661.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Wilcken B., Banforth F., Li Z. et al. Geographical and ethnic variation of the 677 C-T allele of 5,10 methylentetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide // Med Genet. 2003. Vol. 40. P. 619–625.</mixed-citation><mixed-citation xml:lang="en">Wilcken B., Banforth F., Li Z. et al. Geographical and ethnic variation of the 677 C-T allele of 5,10 methylentetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide // Med Genet. 2003. Vol. 40. P. 619–625.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
